| Title | Author(s) | Year | View Count |
 | 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B | Liaw, Y; Gane, E; Leung, N; Zeuzem, S; Wang, Y; Lai, CL; Heathcote, EJ; Manns, M; Bzowej, N; Niu, J; Han, S; Hwang, SG; Cakaloglu, Y; Tong, MJ; Papatheodoridis, G; Chen, Y; Brown, NA; Albanis, E; Galil, K; Naoumov, NV | 2009 | 1,826 |
 | Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients | Hsu, CW; Chen, YC; Liaw, YF; Gane, E; Manns, M; Zeuzem, S; Wang, Y; Lai, CL; Hou, J; Leung, N; Bzowej, N; Niu, J; Jia, J; Hwang, SG; Cakaloglu, Y; Ren, H; Papatheodoridis, G; Chen, Y; Bao, W; Lopez, P | 2009 | 303 |
 | Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response | Lai, CL; Gane, E; Hsu, CW; Chen, YC; Thongsawat, S; Wang, Y; Chen, Y; Naoumov, N; Han, SH; Hwang, SG; Lim, SG; Brown, NA | 2007 | 109 |
 | Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients | DiBisceglie A, A; Lai, CL; Gane, E; Chen, YC; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Zeuzem, S; Rasenack, J; Bzowej, N; Han, SH; Naoumov, N; Hwang, SG; Lim, SG; Chao, GC; Fielman, BA; Brown, NA; Study Group The GLOBE, | 2006 | 159 |
|